このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

新たに診断されたMGMT非メチル化神経膠芽腫に対する免疫療法薬イピリムマブおよびニボルマブと放射線療法の使用を通常の治療(テモゾロミドおよび放射線療法)と比較した試験

2026年10月16日 更新者:National Cancer Institute (NCI)

新たに診断されたMGMT(腫瘍O-6-メチルグアニンDNAメチルトランスフェラーゼ)非メチル化膠芽腫患者におけるイピリムマブとニボルマブ対テモゾロミドの無作為化第II/III相非盲検試験

This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)

SECONDARY OBJECTIVES:

I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.

II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.

III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.

IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.

V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.

VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.

EXPLORATORY OBJECTIVES:

I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:

Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.

III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.

ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.

After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.

研究の種類

介入

入学 (実際)

159

段階

  • フェーズ2
  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • University of Alabama at Birmingham Cancer Center
    • Arkansas
      • Little Rock、Arkansas、アメリカ、72205
        • University of Arkansas for Medical Sciences
    • California
      • Anaheim、California、アメリカ、92806
        • Kaiser Permanente-Anaheim
      • Auburn、California、アメリカ、95602
        • Sutter Auburn Faith Hospital
      • Auburn、California、アメリカ、95603
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
      • Concord、California、アメリカ、94520
        • John Muir Medical Center-Concord
      • La Jolla、California、アメリカ、92093
        • UC San Diego Moores Cancer Center
      • Loma Linda、California、アメリカ、92354
        • Loma Linda University Medical Center
      • Los Angeles、California、アメリカ、90027
        • Kaiser Permanente Los Angeles Medical Center
      • Los Angeles、California、アメリカ、90048
        • Cedars Sinai Medical Center
      • Ontario、California、アメリカ、91761
        • Kaiser Permanente-Ontario
      • Orange、California、アメリカ、92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Roseville、California、アメリカ、95661
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
      • Roseville、California、アメリカ、95661
        • Sutter Roseville Medical Center
      • Sacramento、California、アメリカ、95816
        • Sutter Medical Center Sacramento
      • Sacramento、California、アメリカ、95817
        • University of California Davis Comprehensive Cancer Center
      • Torrance、California、アメリカ、90509
        • Torrance Memorial Medical Center
      • Torrance、California、アメリカ、90505
        • Torrance Memorial Physician Network - Cancer Care
      • Walnut Creek、California、アメリカ、94598
        • John Muir Medical Center-Walnut Creek
    • Colorado
      • Colorado Springs、Colorado、アメリカ、80907
        • Penrose-Saint Francis Healthcare
      • Denver、Colorado、アメリカ、80210
        • AdventHealth Porter
      • Littleton、Colorado、アメリカ、80122
        • AdventHealth Littleton
      • Parker、Colorado、アメリカ、80138
        • AdventHealth Parker
    • Connecticut
      • Hartford、Connecticut、アメリカ、06102
        • Hartford Hospital
      • New Britain、Connecticut、アメリカ、06050
        • The Hospital of Central Connecticut
    • Delaware
      • Lewes、Delaware、アメリカ、19958
        • Beebe Medical Center
      • Millville、Delaware、アメリカ、19967
        • Beebe South Coastal Health Campus
      • Newark、Delaware、アメリカ、19713
        • Helen F Graham Cancer Center
      • Newark、Delaware、アメリカ、19713
        • Delaware Clinical and Laboratory Physicians PA
      • Newark、Delaware、アメリカ、19713
        • Medical Oncology Hematology Consultants PA
      • Newark、Delaware、アメリカ、19718
        • Christiana Care Health System-Christiana Hospital
      • Rehoboth Beach、Delaware、アメリカ、19971
        • Beebe Health Campus
    • Florida
      • Jacksonville、Florida、アメリカ、32207
        • Baptist MD Anderson Cancer Center
      • Orlando、Florida、アメリカ、32803
        • AdventHealth Orlando
    • Georgia
      • Augusta、Georgia、アメリカ、30912
        • Augusta University Medical Center
      • Savannah、Georgia、アメリカ、31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
      • Savannah、Georgia、アメリカ、31404
        • Memorial Health University Medical Center
      • Thomasville、Georgia、アメリカ、31792
        • Lewis Hall Singletary Oncology Center
    • Hawaii
      • Honolulu、Hawaii、アメリカ、96813
        • Queen's Medical Center
      • Honolulu、Hawaii、アメリカ、96817
        • The Cancer Center of Hawaii-Liliha
      • Honolulu、Hawaii、アメリカ、96813
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu、Hawaii、アメリカ、96813
        • Queen's Cancer Cenrer - POB I
      • Honolulu、Hawaii、アメリカ、96813
        • Straub Clinic and Hospital
      • Honolulu、Hawaii、アメリカ、96813
        • University of Hawaii Cancer Center
      • Honolulu、Hawaii、アメリカ、96817
        • Hawaii Cancer Care Inc-Liliha
      • Honolulu、Hawaii、アメリカ、96817
        • Queen's Cancer Center - Kuakini
      • Honolulu、Hawaii、アメリカ、96826
        • Kapiolani Medical Center for Women and Children
      • Honolulu、Hawaii、アメリカ、96813
        • Island Urology
      • Kailua、Hawaii、アメリカ、96734
        • Castle Medical Center
      • Lihue、Hawaii、アメリカ、96766
        • Wilcox Memorial Hospital and Kauai Medical Clinic
      • ‘Aiea、Hawaii、アメリカ、96701
        • Hawaii Cancer Care - Westridge
      • ‘Aiea、Hawaii、アメリカ、96701
        • Pali Momi Medical Center
      • ‘Aiea、Hawaii、アメリカ、96701
        • Queen's Cancer Center - Pearlridge
      • ‘Aiea、Hawaii、アメリカ、96701
        • The Cancer Center of Hawaii-Pali Momi
    • Idaho
      • Boise、Idaho、アメリカ、83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell、Idaho、アメリカ、83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Fruitland、Idaho、アメリカ、83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian、Idaho、アメリカ、83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa、Idaho、アメリカ、83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa、Idaho、アメリカ、83687
        • Saint Luke's Cancer Institute - Nampa
      • Twin Falls、Idaho、アメリカ、83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Bloomington、Illinois、アメリカ、61704
        • Illinois CancerCare-Bloomington
      • Canton、Illinois、アメリカ、61520
        • Illinois CancerCare-Canton
      • Carthage、Illinois、アメリカ、62321
        • Illinois CancerCare-Carthage
      • Centralia、Illinois、アメリカ、62801
        • Centralia Oncology Clinic
      • Chicago、Illinois、アメリカ、60611
        • Northwestern University
      • Chicago、Illinois、アメリカ、60612
        • University of Illinois
      • Danville、Illinois、アメリカ、61832
        • Carle at The Riverfront
      • DeKalb、Illinois、アメリカ、60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur、Illinois、アメリカ、62526
        • Decatur Memorial Hospital
      • Decatur、Illinois、アメリカ、62526
        • Cancer Care Specialists of Illinois - Decatur
      • Effingham、Illinois、アメリカ、62401
        • Crossroads Cancer Center
      • Effingham、Illinois、アメリカ、62401
        • Carle Physician Group-Effingham
      • Elmhurst、Illinois、アメリカ、60126
        • Elmhurst Memorial Hospital
      • Eureka、Illinois、アメリカ、61530
        • Illinois CancerCare-Eureka
      • Evanston、Illinois、アメリカ、60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg、Illinois、アメリカ、61401
        • Western Illinois Cancer Treatment Center
      • Galesburg、Illinois、アメリカ、61401
        • Illinois CancerCare-Galesburg
      • Geneva、Illinois、アメリカ、60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview、Illinois、アメリカ、60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Highland Park、Illinois、アメリカ、60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Kewanee、Illinois、アメリカ、61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb、Illinois、アメリカ、61455
        • Illinois CancerCare-Macomb
      • Mattoon、Illinois、アメリカ、61938
        • Carle Physician Group-Mattoon/Charleston
      • Naperville、Illinois、アメリカ、60540
        • Edward Hospital/Cancer Center
      • O'Fallon、Illinois、アメリカ、62269
        • Cancer Care Center of O'Fallon
      • Ottawa、Illinois、アメリカ、61350
        • Illinois CancerCare-Ottawa Clinic
      • Park Ridge、Illinois、アメリカ、60068
        • Advocate Lutheran General Hospital
      • Pekin、Illinois、アメリカ、61554
        • Illinois CancerCare-Pekin
      • Peoria、Illinois、アメリカ、61636
        • Methodist Medical Center of Illinois
      • Peoria、Illinois、アメリカ、61637
        • OSF Saint Francis Medical Center
      • Peoria、Illinois、アメリカ、61615
        • Illinois CancerCare-Peoria
      • Peru、Illinois、アメリカ、61354
        • Illinois CancerCare-Peru
      • Princeton、Illinois、アメリカ、61356
        • Illinois CancerCare-Princeton
      • Rockford、Illinois、アメリカ、61114
        • UW Health Carbone Cancer Center Rockford
      • Springfield、Illinois、アメリカ、62702
        • Southern Illinois University School of Medicine
      • Springfield、Illinois、アメリカ、62702
        • Springfield Clinic
      • Springfield、Illinois、アメリカ、62781
        • Springfield Memorial Hospital
      • Urbana、Illinois、アメリカ、61801
        • Carle Cancer Center
      • Urbana、Illinois、アメリカ、61801
        • The Carle Foundation Hospital
      • Warrenville、Illinois、アメリカ、60555
        • Northwestern Medicine Cancer Center Warrenville
      • Washington、Illinois、アメリカ、61571
        • Illinois CancerCare - Washington
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Indianapolis、Indiana、アメリカ、46202
        • IU Health Methodist Hospital
    • Iowa
      • Ames、Iowa、アメリカ、50010
        • Mary Greeley Medical Center
      • Ames、Iowa、アメリカ、50010
        • McFarland Clinic - Ames
      • Clive、Iowa、アメリカ、50325
        • Mercy Cancer Center-West Lakes
      • Clive、Iowa、アメリカ、50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Council Bluffs、Iowa、アメリカ、51503
        • Heartland Oncology and Hematology LLP
      • Council Bluffs、Iowa、アメリカ、51503
        • Methodist Jennie Edmundson Hospital
      • Creston、Iowa、アメリカ、50801
        • Greater Regional Medical Center
      • Des Moines、Iowa、アメリカ、50309
        • Iowa Methodist Medical Center
      • Des Moines、Iowa、アメリカ、50314
        • Mercy Medical Center - Des Moines
      • Des Moines、Iowa、アメリカ、50314
        • Broadlawns Medical Center
      • Des Moines、Iowa、アメリカ、50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines、Iowa、アメリカ、50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • West Des Moines、Iowa、アメリカ、50266
        • Mercy Medical Center-West Lakes
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • University of Kentucky/Markey Cancer Center
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70112
        • Tulane University School of Medicine
      • New Orleans、Louisiana、アメリカ、70121
        • Ochsner Medical Center Jefferson
    • Maine
      • Bangor、Maine、アメリカ、04401
        • Eastern Maine Medical Center
      • Bath、Maine、アメリカ、04530
        • MaineHealth Coastal Cancer Treatment Center
      • Belfast、Maine、アメリカ、04915
        • MaineHealth Waldo Hospital
      • Brewer、Maine、アメリカ、04412
        • Lafayette Family Cancer Center-EMMC
      • Portland、Maine、アメリカ、04102
        • MaineHealth Maine Medical Center - Portland
      • Rockport、Maine、アメリカ、04856
        • Penobscot Bay Medical Center
      • Sanford、Maine、アメリカ、04073
        • MaineHealth Cancer Care Center of York County
      • Scarborough、Maine、アメリカ、04074
        • Maine Medical Partners Neurology
      • Scarborough、Maine、アメリカ、04074
        • MaineHealth Maine Medical Center- Scarborough
      • South Portland、Maine、アメリカ、04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
    • Maryland
      • Baltimore、Maryland、アメリカ、21201
        • University of Maryland/Greenebaum Cancer Center
      • Bel Air、Maryland、アメリカ、21014
        • UM Upper Chesapeake Medical Center
      • Columbia、Maryland、アメリカ、21044
        • Central Maryland Radiation Oncology in Howard County
      • Glen Burnie、Maryland、アメリカ、21061
        • UM Baltimore Washington Medical Center/Tate Cancer Center
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brighton、Michigan、アメリカ、48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Brighton、Michigan、アメリカ、48114
        • Trinity Health Medical Center - Brighton
      • Canton、Michigan、アメリカ、48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Canton、Michigan、アメリカ、48188
        • Trinity Health Medical Center - Canton
      • Chelsea、Michigan、アメリカ、48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Chelsea、Michigan、アメリカ、48118
        • Chelsea Hospital
      • Dearborn、Michigan、アメリカ、48124
        • Corewell Health Dearborn Hospital
      • Detroit、Michigan、アメリカ、48236
        • Henry Ford Health Saint John Hospital
      • Flint、Michigan、アメリカ、48503
        • Hurley Medical Center
      • Flint、Michigan、アメリカ、48503
        • Genesys Hurley Cancer Institute
      • Grand Rapids、Michigan、アメリカ、49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Kalamazoo、Michigan、アメリカ、49007
        • West Michigan Cancer Center
      • Kalamazoo、Michigan、アメリカ、49007
        • Bronson Methodist Hospital
      • Kalamazoo、Michigan、アメリカ、49048
        • Beacon Kalamazoo
      • Livonia、Michigan、アメリカ、48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Pontiac、Michigan、アメリカ、48341
        • Michigan Healthcare Professionals Pontiac
      • Royal Oak、Michigan、アメリカ、48073
        • Corewell Health William Beaumont University Hospital
      • Saginaw、Michigan、アメリカ、48604
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw、Michigan、アメリカ、48601
        • MyMichigan Medical Center Saginaw
      • Tawas City、Michigan、アメリカ、48764
        • MyMichigan Medical Center Tawas
      • Troy、Michigan、アメリカ、48085
        • Corewell Health Beaumont Troy Hospital
      • Warren、Michigan、アメリカ、48093
        • Henry Ford Health Warren Hospital
      • West Branch、Michigan、アメリカ、48661
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Wyoming、Michigan、アメリカ、49519
        • University of Michigan Health - West
      • Ypsilanti、Michigan、アメリカ、48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    • Minnesota
      • Bemidji、Minnesota、アメリカ、56601
        • Sanford Joe Lueken Cancer Center
      • Burnsville、Minnesota、アメリカ、55337
        • Fairview Ridges Hospital
      • Burnsville、Minnesota、アメリカ、55337
        • Minnesota Oncology - Burnsville
      • Coon Rapids、Minnesota、アメリカ、55433
        • Mercy Hospital
      • Edina、Minnesota、アメリカ、55435
        • Fairview Southdale Hospital
      • Fridley、Minnesota、アメリカ、55432
        • Unity Hospital
      • Maple Grove、Minnesota、アメリカ、55369
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood、Minnesota、アメリカ、55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis、Minnesota、アメリカ、55415
        • Hennepin County Medical Center
      • Minneapolis、Minnesota、アメリカ、55454
        • Health Partners Inc
      • Saint Louis Park、Minnesota、アメリカ、55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul、Minnesota、アメリカ、55101
        • Regions Hospital
      • Saint Paul、Minnesota、アメリカ、55102
        • United Hospital
      • Stillwater、Minnesota、アメリカ、55082
        • Lakeview Hospital
    • Mississippi
      • Jackson、Mississippi、アメリカ、39216
        • University of Mississippi Medical Center
      • Southhaven、Mississippi、アメリカ、38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • Cape Girardeau、Missouri、アメリカ、63703
        • Saint Francis Medical Center
    • Montana
      • Billings、Montana、アメリカ、59101
        • Billings Clinic Cancer Center
      • Bozeman、Montana、アメリカ、59715
        • Bozeman Health Deaconess Hospital
      • Butte、Montana、アメリカ、59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls、Montana、アメリカ、59405
        • Benefis Sletten Cancer Institute
      • Kalispell、Montana、アメリカ、59901
        • Logan Health Medical Center
    • Nebraska
      • Bellevue、Nebraska、アメリカ、68123
        • Nebraska Medicine-Bellevue
      • Lincoln、Nebraska、アメリカ、68516
        • Cancer Partners of Nebraska
      • Omaha、Nebraska、アメリカ、68114
        • Nebraska Methodist Hospital
      • Omaha、Nebraska、アメリカ、68198
        • University of Nebraska Medical Center
      • Omaha、Nebraska、アメリカ、68118
        • Nebraska Medicine-Village Pointe
    • New Hampshire
      • Lebanon、New Hampshire、アメリカ、03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • New Jersey
      • Hackensack、New Jersey、アメリカ、07601
        • Hackensack University Medical Center
      • Livingston、New Jersey、アメリカ、07039
        • Saint Barnabas Medical Center
      • Morristown、New Jersey、アメリカ、07960
        • Morristown Medical Center
      • Neptune City、New Jersey、アメリカ、07753
        • Jersey Shore Medical Center
      • New Brunswick、New Jersey、アメリカ、08903
        • Rutgers Cancer Institute of New Jersey
      • Pennington、New Jersey、アメリカ、08534
        • Capital Health Medical Center-Hopewell
      • Summit、New Jersey、アメリカ、07902
        • Overlook Hospital
    • New York
      • New York、New York、アメリカ、10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York、New York、アメリカ、10065
        • NYP/Weill Cornell Medical Center
      • New York、New York、アメリカ、10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Rochester、New York、アメリカ、14642
        • University of Rochester
      • Syracuse、New York、アメリカ、13210
        • State University of New York Upstate Medical University
      • West Islip、New York、アメリカ、11795
        • Good Samaritan University Hospital
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Charlotte、North Carolina、アメリカ、28210
        • Atrium Health Pineville/LCI-Pineville
      • Concord、North Carolina、アメリカ、28025
        • Atrium Health Cabarrus/LCI-Concord
    • North Dakota
      • Bismarck、North Dakota、アメリカ、58501
        • Sanford Bismarck Medical Center
      • Fargo、North Dakota、アメリカ、58122
        • Sanford Roger Maris Cancer Center
      • Fargo、North Dakota、アメリカ、58122
        • Sanford Broadway Medical Center
    • Ohio
      • Akron、Ohio、アメリカ、44304
        • Summa Health System - Akron Campus
      • Cleveland、Ohio、アメリカ、44106
        • Case Western Reserve University
      • Cleveland、Ohio、アメリカ、44195
        • Cleveland Clinic Foundation
      • Columbus、Ohio、アメリカ、43214
        • Riverside Methodist Hospital
      • Dublin、Ohio、アメリカ、43016
        • Dublin Methodist Hospital
    • Oklahoma
      • Lawton、Oklahoma、アメリカ、73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City、Oklahoma、アメリカ、73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Clackamas、Oregon、アメリカ、97015
        • Clackamas Radiation Oncology Center
      • Clackamas、Oregon、アメリカ、97015
        • Providence Cancer Institute Clackamas Clinic
      • Gresham、Oregon、アメリカ、97030
        • Legacy Mount Hood Medical Center
      • Newberg、Oregon、アメリカ、97132
        • Providence Newberg Medical Center
      • Portland、Oregon、アメリカ、97210
        • Legacy Good Samaritan Hospital and Medical Center
      • Portland、Oregon、アメリカ、97213
        • Providence Portland Medical Center
      • Portland、Oregon、アメリカ、97225
        • Providence Saint Vincent Medical Center
      • Portland、Oregon、アメリカ、97227
        • Kaiser Permanente Northwest
      • Tualatin、Oregon、アメリカ、97062
        • Legacy Meridian Park Hospital
    • Pennsylvania
      • Allentown、Pennsylvania、アメリカ、18103
        • Lehigh Valley Hospital-Cedar Crest
      • Broomall、Pennsylvania、アメリカ、19008
        • Crozer-Keystone Regional Cancer Center at Broomall
      • Chadds Ford、Pennsylvania、アメリカ、19317
        • Christiana Care Health System-Concord Health Center
      • Lancaster、Pennsylvania、アメリカ、17601
        • Lancaster General Ann B Barshinger Cancer Institute
      • Lancaster、Pennsylvania、アメリカ、17602
        • Lancaster General Hospital
      • Monroeville、Pennsylvania、アメリカ、15146
        • Forbes Hospital
      • Philadelphia、Pennsylvania、アメリカ、19107
        • Thomas Jefferson University Hospital
      • Pittsburgh、Pennsylvania、アメリカ、15212
        • Allegheny General Hospital
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • University of Pittsburgh Cancer Institute (UPCI)
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC-Shadyside Hospital
      • West Reading、Pennsylvania、アメリカ、19611
        • Reading Hospital
      • Wexford、Pennsylvania、アメリカ、15090
        • Wexford Health and Wellness Pavilion
    • South Carolina
      • Rock Hill、South Carolina、アメリカ、29730
        • Rock Hill Radiation Therapy Center
    • South Dakota
      • Pierre、South Dakota、アメリカ、57501
        • Avera Cancer Institute at Pierre
      • Sioux Falls、South Dakota、アメリカ、57105
        • Avera Cancer Institute
      • Sioux Falls、South Dakota、アメリカ、57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls、South Dakota、アメリカ、57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Collierville、Tennessee、アメリカ、38017
        • Baptist Memorial Hospital and Cancer Center-Collierville
      • Memphis、Tennessee、アメリカ、38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Texas
      • Houston、Texas、アメリカ、77030
        • Memorial Hermann Texas Medical Center
      • San Antonio、Texas、アメリカ、78229
        • University of Texas Health Science Center at San Antonio
    • Utah
      • American Fork、Utah、アメリカ、84003
        • American Fork Hospital / Huntsman Intermountain Cancer Center
      • Cedar City、Utah、アメリカ、84720
        • Sandra L Maxwell Cancer Center
      • Logan、Utah、アメリカ、84321
        • Logan Regional Hospital
      • Murray、Utah、アメリカ、84107
        • Intermountain Medical Center
      • Ogden、Utah、アメリカ、84403
        • McKay-Dee Hospital Center
      • Provo、Utah、アメリカ、84604
        • Utah Valley Regional Medical Center
      • Riverton、Utah、アメリカ、84065
        • Riverton Hospital
      • Salt Lake City、Utah、アメリカ、84112
        • Huntsman Cancer Institute/University of Utah
      • Salt Lake City、Utah、アメリカ、84143
        • LDS Hospital
      • St. George、Utah、アメリカ、84770
        • Saint George Regional Medical Center
    • Vermont
      • Berlin Corners、Vermont、アメリカ、05602
        • Central Vermont Medical Center/National Life Cancer Treatment
      • Burlington、Vermont、アメリカ、05401
        • University of Vermont Medical Center
      • Burlington、Vermont、アメリカ、05405
        • University of Vermont and State Agricultural College
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • Inova Schar Cancer Institute
      • Richmond、Virginia、アメリカ、23298
        • VCU Massey Comprehensive Cancer Center
      • South Hill、Virginia、アメリカ、23970
        • VCU Community Memorial Health Center
    • Washington
      • Seattle、Washington、アメリカ、98101
        • Virginia Mason Medical Center
      • Vancouver、Washington、アメリカ、98686
        • Legacy Salmon Creek Hospital
      • Vancouver、Washington、アメリカ、98684
        • Legacy Cancer Institute Medical Oncology and Day Treatment
    • West Virginia
      • Wheeling、West Virginia、アメリカ、26003
        • Wheeling Hospital/Schiffler Cancer Center
    • Wisconsin
      • Burlington、Wisconsin、アメリカ、53105
        • Aurora Cancer Care-Southern Lakes VLCC
      • Germantown、Wisconsin、アメリカ、53022
        • Aurora Health Care Germantown Health Center
      • Grafton、Wisconsin、アメリカ、53024
        • Aurora Cancer Care-Grafton
      • Green Bay、Wisconsin、アメリカ、54311
        • Aurora BayCare Medical Center
      • Johnson Creek、Wisconsin、アメリカ、53038
        • University of Wisconsin Carbone Cancer Center - Johnson Creek
      • Kenosha、Wisconsin、アメリカ、53142
        • Aurora Cancer Care-Kenosha South
      • Madison、Wisconsin、アメリカ、53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Marinette、Wisconsin、アメリカ、54143
        • Aurora Bay Area Medical Group-Marinette
      • Milwaukee、Wisconsin、アメリカ、53209
        • Aurora Cancer Care-Milwaukee
      • Milwaukee、Wisconsin、アメリカ、53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee、Wisconsin、アメリカ、53233
        • Aurora Sinai Medical Center
      • Minocqua、Wisconsin、アメリカ、54548
        • Marshfield Medical Center - Minocqua
      • New Richmond、Wisconsin、アメリカ、54017
        • Cancer Center of Western Wisconsin
      • Oshkosh、Wisconsin、アメリカ、54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Racine、Wisconsin、アメリカ、53406
        • Aurora Cancer Care-Racine
      • Sheboygan、Wisconsin、アメリカ、53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Summit、Wisconsin、アメリカ、53066
        • Aurora Medical Center in Summit
      • Two Rivers、Wisconsin、アメリカ、54241
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Wauwatosa、Wisconsin、アメリカ、53226
        • Aurora Cancer Care-Milwaukee West
      • West Allis、Wisconsin、アメリカ、53227
        • Aurora West Allis Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • PRIOR TO STEP 1 REGISTRATION:

  • No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)

  • Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis

    • Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
  • Contrast-enhanced brain MRI within 3 days after surgery

    • MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
    • 3D pre contrast-enhanced T1 sequences are strongly suggested
  • Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry

  • PRIOR TO STEP 2 REGISTRATION:

  • Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review

    • Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
  • MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.

    • Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
    • Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
  • IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)

    • Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
  • History/physical examination within 28 days prior to step 2 registration

  • Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration

  • Neurologic function assessment within 28 days prior to step 2 registration

  • Age >= 18 years

  • Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)

  • Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)

  • Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)

  • Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)

  • Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)

  • Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)

  • Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)

  • Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start

    • Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes

Exclusion Criteria:

  • Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;

    • Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
  • Current or planned treatment with any other investigational agents for the study cancer

  • Definitive clinical or radiologic evidence of metastatic disease outside the brain

  • Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years

  • Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields

  • Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants

  • History of severe hypersensitivity reaction to any monoclonal antibody

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide

  • On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed

  • Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody

  • History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)

  • Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease

    • Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:

      • Vitiligo

      • Type I diabetes

      • Rheumatoid arthritis and other arthropathies

      • Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)

        • Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
  • Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded

  • Current or planned therapy with warfarin

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Arm I (radiation therapy, temozolomide)

Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial.

Ancillary studies

他の名前:
  • 生活の質の評価

Ancillary studies

Given PO

他の名前:
  • テモダール
  • SCH 52365
  • テモーダル
  • Temcad
  • メタゾラストン
  • RP-46161
  • テモメダク
  • TMZ
  • CCRG-81045
  • イミダゾ[5,1-d]-1,2,3,5-テトラジン-8-カルボキサミド、3,4-ジヒドロ-3-メチル-4-オキソ-
  • M&B 39831
  • エムアンドビー 39831
  • グリオテム
  • テミゾール

Undergo radiation therapy

他の名前:
  • がん放射線治療
  • ENERGY_TYPE
  • 照射する
  • 照射された
  • 照射
  • 放射線
  • 放射線治療、NOS
  • 放射線治療学
  • 放射線治療
  • RT
  • 治療、放射線
  • エネルギーの種類

Undergo contrast-enhanced brain MRI

他の名前:
  • 造影MRI

Wear Optune device

他の名前:
  • オプチューン
  • ノボTTF-100A
  • NovoTTF-100A システム
  • ノボTTフィールド
  • NovoTumor 治療分野
  • オプチューン デバイス
  • NovoTTF-100A システム (Optune)
実験的:Arm II (radiation therapy, ipilimumab, nivolumab)

Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.

Ancillary studies

他の名前:
  • 生活の質の評価

Given IV

他の名前:
  • 抗細胞傷害性 T リンパ球関連抗原 4 モノクローナル抗体
  • BMS-734016
  • イピリムマブ バイオシミラー CS1002
  • MDX-010
  • MDX-CTLA4
  • ヤーボイ
  • MDX010
  • BMS734016
  • BMS 734016

Ancillary studies

Given IV

他の名前:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • オプジーボ
  • CMAB819
  • ニボルマブ バイオシミラー CMAB819
  • MDX1106
  • BMS 936558
  • ABP206
  • ニボルマブ バイオシミラー ABP 206
  • BCD-263
  • ニボルマブ バイオシミラー BCD-263
  • BMS936558
  • 小野 4538
  • オノ4538

Undergo radiation therapy

他の名前:
  • がん放射線治療
  • ENERGY_TYPE
  • 照射する
  • 照射された
  • 照射
  • 放射線
  • 放射線治療、NOS
  • 放射線治療学
  • 放射線治療
  • RT
  • 治療、放射線
  • エネルギーの種類

Undergo contrast-enhanced brain MRI

他の名前:
  • 造影MRI

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression-free Survival (PFS) (Phase II)
時間枠:From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.

Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method.

From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
Overall Survival (OS) (Phase III)
時間枠:From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.

Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method.

From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.

二次結果の測定

結果測定
メジャーの説明
時間枠
PFS for the Entire Cohort (Phase II/III)
時間枠:From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.

Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method.

From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
Overall Survival at 2 Years
時間枠:From randomization to two years

Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method.

From randomization to two years
Number of Participants by Highest Grade Adverse Event Reported
時間枠:From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.

Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
時間枠:Baseline and six months

The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months.

Baseline and six months
Time to Neurocognitive Failure
時間枠:From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.

Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1.

From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
時間枠:Six months

Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response.

Six months

その他の成果指標

結果測定
メジャーの説明
時間枠
OS (研究がフェーズ II で中止された場合)
時間枠:研究の第 II 相終了時
研究の第 II 相終了時
Tumor Biomarker Analyses
時間枠:Up to 4 years

Will assess PD-L1 expression and mutational burden expression specifically.

Up to 4 years
MGMT Protein Expression
時間枠:Up to 4 years

Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions.

Up to 4 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Andrew B Lassman、NRG Oncology

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年9月1日

一次修了 (実際)

2023年1月13日

研究の完了 (実際)

2025年12月23日

試験登録日

最初に提出

2020年5月20日

QC基準を満たした最初の提出物

2020年5月20日

最初の投稿 (実際)

2020年5月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年10月16日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する